CN109588720A - 一种具有提高缺氧耐受力作用的保健食品及其制备方法 - Google Patents
一种具有提高缺氧耐受力作用的保健食品及其制备方法 Download PDFInfo
- Publication number
- CN109588720A CN109588720A CN201910037759.XA CN201910037759A CN109588720A CN 109588720 A CN109588720 A CN 109588720A CN 201910037759 A CN201910037759 A CN 201910037759A CN 109588720 A CN109588720 A CN 109588720A
- Authority
- CN
- China
- Prior art keywords
- health food
- alcohol
- anoxia endurance
- root
- ginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010021143 Hypoxia Diseases 0.000 title claims abstract description 37
- 206010002660 Anoxia Diseases 0.000 title claims abstract description 33
- 241000976983 Anoxia Species 0.000 title claims abstract description 32
- 230000007953 anoxia Effects 0.000 title claims abstract description 32
- 230000000694 effects Effects 0.000 title claims abstract description 32
- 235000013402 health food Nutrition 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 77
- 239000003814 drug Substances 0.000 claims abstract description 33
- 241001165494 Rhodiola Species 0.000 claims abstract description 28
- 241000208340 Araliaceae Species 0.000 claims abstract description 23
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 23
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 23
- 235000008434 ginseng Nutrition 0.000 claims abstract description 23
- 235000019441 ethanol Nutrition 0.000 claims description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000006071 cream Substances 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 14
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 13
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 13
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 10
- 241001072909 Salvia Species 0.000 claims description 9
- 235000017276 Salvia Nutrition 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- 239000006286 aqueous extract Substances 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- 238000007873 sieving Methods 0.000 claims description 8
- 239000011122 softwood Substances 0.000 claims description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
- 229920000881 Modified starch Polymers 0.000 claims description 7
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
- 239000000080 wetting agent Substances 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- -1 hydroxy-propyl Chemical group 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000000643 oven drying Methods 0.000 claims description 4
- 239000008188 pellet Substances 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 4
- 238000004064 recycling Methods 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- 235000020985 whole grains Nutrition 0.000 claims description 4
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 3
- 150000001336 alkenes Chemical class 0.000 claims 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 29
- 239000001301 oxygen Substances 0.000 abstract description 29
- 229910052760 oxygen Inorganic materials 0.000 abstract description 29
- 239000008280 blood Substances 0.000 abstract description 11
- 210000004369 blood Anatomy 0.000 abstract description 10
- 208000027418 Wounds and injury Diseases 0.000 abstract description 5
- 230000006378 damage Effects 0.000 abstract description 5
- 208000014674 injury Diseases 0.000 abstract description 5
- 230000001146 hypoxic effect Effects 0.000 abstract description 2
- 230000004060 metabolic process Effects 0.000 abstract description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract 2
- 238000009825 accumulation Methods 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 235000014655 lactic acid Nutrition 0.000 abstract 1
- 239000004310 lactic acid Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 16
- 238000011282 treatment Methods 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 10
- 238000011049 filling Methods 0.000 description 9
- 230000033001 locomotion Effects 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
- 229960003957 dexamethasone Drugs 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 235000020710 ginseng extract Nutrition 0.000 description 5
- 235000010288 sodium nitrite Nutrition 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000014644 Brain disease Diseases 0.000 description 3
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 238000001467 acupuncture Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 238000002639 hyperbaric oxygen therapy Methods 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 206010011703 Cyanosis Diseases 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 2
- 229960000571 acetazolamide Drugs 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 230000002802 cardiorespiratory effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- HUAUNKAZQWMVFY-UHFFFAOYSA-M sodium;oxocalcium;hydroxide Chemical compound [OH-].[Na+].[Ca]=O HUAUNKAZQWMVFY-UHFFFAOYSA-M 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009244 Claustrophobia Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241001646834 Mesona Species 0.000 description 1
- 206010038664 Respiratory alkalosis Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 208000027719 adult hypothyroidism Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 108091008690 chemoreceptors Proteins 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种具有提高缺氧耐受力作用的保健食品及其制备方法,涉及中药保健食品。所述保健食品中包含红景天、人参、丹参,将红景天、人参、丹参进行醇提和水煎,获得了其精华成分。本发明的保健食品具有提高缺氧耐受力的作用,可减弱体内缺氧对机体的伤害程度,提升生活质量。本发明的保健食品可以促进血液运行,增大血氧含量,排除乳酸堆积,提高新陈代谢,帮助服用者改善缺氧症状。
Description
技术领域
本发明涉及中药保健食品,具体而言,涉及一种用于提高缺氧耐受力作用的保健食品及其制备方法。
背景技术
氧,是人类赖以生存的气体,在空气中的含量约为21%,理论上可以满足正常人的身体需要。但由于空气污染、心脑血管疾病、呼吸系统疾病和高强度用脑等原因,往往会导致人缺氧。调查表明,90%的城市人口处于不同程度的缺氧状态。缺氧正成为威胁许多人健康的无形杀手。氧为机体新陈代谢过程中的必需物质,缺氧则是许多疾病开始发生的基础,有研究表明高原低氧可导致健康成人甲状腺功能减退。那么在现代的形势中,环境污染的加剧、巨大的工作压力和快节奏的生活,这些都无时不刻在威胁人类的健康。缺氧能够导致高血压、糖尿病、冠心病、呼吸疾病、脑部疾病、消化疾病、关节痛、痛风、前列腺炎、紫绀、肿瘤癌症、亚健康等一系列危害身体健康的疾病。截至目前,提高机体缺氧耐受力的主要方法有高压氧治疗、有氧运动和药物治疗。
高压氧治疗,是在高压(超过常压)的环境下,呼吸纯氧或高浓度氧以治疗缺氧性疾病。相关治疗方法:1、纯氧舱:用纯氧加压,稳压后病人直接呼吸舱内的氧。优点:体积小,价格低,易于运输,很受中小医院的欢迎。缺点:加压介质为氧气,极易引起火灾,化纤织物绝对不能进舱,进舱人员必须着全棉衣物进舱,国内、外氧舱燃烧事故多发生在该种舱型;一次治疗最多只允许一个病人进舱治疗,部分病人会出现幽闭恐惧症;医务人员一般不能进舱,一旦舱内有情况,难以及时处理,不利于危重和病情不稳定病人的救治。2、空气加压舱:用空气加压,稳压后根据病情,病人通过面罩、氧帐,直至人工呼吸吸氧。优点:安全,体积较大,一次可容纳多个病人进舱治疗,治疗环境比较轻松;允许医务人员进舱,利于危重病人和病情不稳定病人的救治;如有必要可在舱内实施手术。缺点:体积较大,运输不便,价格昂贵。3、高压氧治疗设备除了高压氧舱以外,还有空气压缩机以产生压缩空气,储气罐以储备压缩空气,空调系统,监视设备,对讲设备,控制台等。该方法在国内主要应用于缺血缺氧性脑病,而在国外文献报道中,国际研究小组进行的随机对照研究发现,高压氧对缺血缺氧性脑病无任何疗效。
有氧运动是指人体在氧气充分供应的情况下进行的体育锻炼。即在运动过程中,人体吸入的氧气与需求相等,达到生理上的平衡状态。有氧运动的目的在于增强心肺耐力。运动时,由于肌肉收缩而需要大量养分和氧气,心脏的收缩次数便增加,而且每次压送出的血液量也较平常多,同时,氧气的需求量亦增加,呼吸次数比正常多,肺部的收张程度也较大。所以当运动持续,肌肉长时间收缩,心肺就必须努力地供应氧气分给肌肉,以及运走肌肉中的废物。而这持续性的需求,可提高心肺耐力。有氧运动主要有跑步、跳绳、健美操、球类运动、游泳、自行车运动、登山等运动。因为有大肌肉群参与运动,所以走跑运动对人体的锻炼刺激效果比较明显,尤其是对人体心肺功能有比较好的强化作用。运动时速度可快可慢,强度可大可小,适合各种体质水平的人。但是,这些运动形式也有一些突出的问题,比如在走步、跑步运动过程中,各个关节的活动范围不大,属于大关节小活动,不能使各个运动的主要关节有大范围或全范围的活动。
药物治疗是现在最主流的形式之一,其主要包括化药治疗和中药治疗,目前化药治疗的药物包括乙酰唑胺和地塞米松,这两种药品在国外用于提高缺氧耐受力深受欢迎。乙酰唑胺是碳酸酐酶抑制剂,可抑制肾脏分泌氢离子,以纠正呼吸性碱中毒状态,促使血液中H+浓度升高,刺激外周及中枢化学感受器,使肺通气量增加而改善缺氧状态,从而减轻缺氧症状,但与此同时,也会引起感觉异常、尿频、肢体麻木等副作用。
地塞米松可以提高体内糖皮质激素浓度,改善机体应激能力,增加细胞膜的稳定性,从而提高组织细胞的抗缺氧能力。地塞米松是一种长效的糖皮质激素,具有抗炎、允许作用等功能;Meta分析地塞米松可降低急性高原反应(Acute High Altitude Reaction,AHAR)发生率,该文章中服用地塞米松片的剂量8-16mg/天,使用剂量较大,可能引起免疫力低下、肾上腺皮质激素功能紊乱等不良反应。在中国人群中,较少有人使用这两种药物预防AHAR,因此筛选适合中国人群使用预防AHAR的药物,是目前AHAR预防用药研究的热点。
在国内“中医养生”、“传统保健”等中医治疗手段日趋流行,在中医治疗“缺氧”方面,其治疗方法可分为外用手法治疗及内服中药治疗。纵观中医古籍,传统中医并没有“缺氧”一词。“缺氧”是现代中医学者根据缺氧性疾病有呼吸困难、心跳加速、紫绀、眩晕、血压偏低、神志混乱、肢体或局部疼痛等临床症状,提出“缺氧”乃为“肺气不足则无以司呼吸,难以贯心脉,因而淤血内阻,故会表现出以上症状”。依据症状,中医在手法治疗方面主要是采用针灸及推拿治疗,如针灸风池、完骨、天柱后加百会、印堂、内关等穴位来缓解脑缺氧症状。
在内服中药治疗方面,中医认为:肺主气,心主血脉,而气者,人之根本。诸气者,皆属于肺。肺司呼吸是人体内部与外界实现气体交换和吐故纳新的主要器官。《诸病源候论·卷三十七》写到“其肺气虚,谓之不足,则短乏少气”;因此中医在运用内服中药治疗“缺氧”这一症状时,主要采用“阴阳平衡、气血双补”的法则进行治疗,依据中药药性、功效及君臣佐使配伍规律,结合临床实践,选取具有抗耐缺氧作用的中药材如人参、丹参、枸杞、红景天等中药材,可以提高机体缺氧耐受力,加速低氧适应的建立,使机体内的儿茶酚胺水平上升,从而提高机体的应激能力和免疫功能。到目前为止,随着我国国力不断攀升,医疗健康产业相关制度与规程越发完善,以中药及其复方制剂缓解和治疗“缺氧”,越来越深受国内外患者的追捧。
发明内容
本发明提供一种具有提高缺氧耐受力作用的保健食品及其制备方法,以改善缺氧症状,使身体各部位重新得到充分的氧气供给,促进血液运行,增大血氧含量,提高新陈代谢。
本发明采取的技术方案是:由如下方法制备的:
1)、分别取处方量的红景天、丹参、人参,所述红景天、丹参、人参的重量比例为4:3:1;
2)、将丹参药材与红景天、人参药材分别加入两个提取罐中,并在提取罐中加入乙醇溶液;
3)、对所述提取罐中的材料进行乙醇提取,过滤,获得相应醇提液及药渣;
4)、在所述提取罐中加入纯化水与三味药渣混合,加热煎煮预定时间,对所得溶液过滤,获得水提液,并对所述水提液进行减压浓缩,获得水提浓缩液;
5)、将步骤3)中所获得的醇提液进行减压浓缩,回收乙醇至无醇味,获得醇提浓缩液;
6)、将所述醇提浓缩液与所述水提浓缩液分别进行减压真空干燥至干膏状;
7)、将步骤6)中两种干膏混匀、粉碎、过筛,得相应干膏粉;
8)、分别取处方量的预胶化淀粉、微晶纤维素、交联聚乙烯吡咯烷酮、低取代羟丙基纤维素,过筛、与上述干膏粉按比例进行混匀;
9)、混匀后,以聚乙烯吡咯烷酮乙醇溶液为润湿剂,制软材;
10)、将上述软材过筛,制成颗粒,烘箱干燥,温度为60℃;
11)、将上述干燥后的颗粒过筛整粒;
12)、取处方量的滑石粉过筛并与上述颗粒混匀后,压片。
本发明在所述步骤3)中进行醇提时,丹参药材所需乙醇浓度为90~95%,提取2~3次,每次1~2小时,提取温度为90℃,溶媒量为4~6倍量;人参、红景天所需乙醇浓度为65~75%,提取2~3次,每次1~2小时,溶媒量为5~7倍量。
本发明在所述步骤4)中进行水提时,所需纯化水用量为6~8倍量,提取2~3次,每次1~2小时。
本发明在所述步骤4)和所述步骤5)的减压浓缩过程中,减压至相对密度为1.05~1.08。
本发明在所述步骤7)、所述步骤8)和所述步骤12)过筛目数应为80目。
本发明在所述步骤10)过筛目数应为40目。
本发明在所述步骤11)过筛目数应为16目。
本发明在所述步骤9)润湿剂应为5%聚乙烯吡咯烷酮的80%乙醇溶液。
本发明步骤8)干膏粉末与辅料粉末的比例为1.5:1;辅料比例应为:微晶纤维素:预胶化淀粉:交联聚乙烯吡咯烷酮:低取代羟丙基纤维素:滑石粉=48.5:13:16.25:20.25:2。
经现代药理研究和临床实验证明,本发明产品具有确切的提高缺氧耐受力的作用,并且无毒副作用。其中红景天味甘、苦,性平。归肺、心经。功能健脾益气,补肺养阴、活血通脉;人参性甘、温,归脾、肺经。功能扶正固本、大补元气、补脾益肺、生津止渴、安神益智、补气生血;丹参味苦,性微寒,入心肝二经。功能活血止痛、养血安神、清心除烦。众药合用,共奏益肺健脾、活血通脉、滋补强壮,扶正固本之功。可有效降低心肌耗氧量,使冠脉、脑血管流量增加,增强机体抵抗力,起到提高缺氧耐受力的保健功能。
在其他实现方式中,本发明还在其中添加了一些辅料,使得产品既能够提高缺氧耐受力又与上面的主要材料配合起到相辅相成的作用。
综上,本发明开发了方便易服、兼具提高缺氧耐受性的保健食品,可减弱体内缺氧对机体的伤害程度,提升生活质量。
具体实施方式
由如下方法制备的:
1)、分别取处方量的红景天、丹参、人参,所述红景天、丹参、人参的重量比例为4:3:1;
2)、将丹参药材与红景天、人参药材分别加入两个提取罐中,并在提取罐中加入乙醇溶液;
3)、对所述提取罐中的材料进行乙醇提取,过滤,获得相应醇提液及药渣;
4)、在所述提取罐中加入纯化水与三味药渣混合,加热煎煮预定时间,对所得溶液过滤,获得水提液,并对所述水提液进行减压浓缩,获得水提浓缩液;
5)、将步骤3)中所获得的醇提液进行减压浓缩,回收乙醇至无醇味,获得醇提浓缩液;
6)、将所述醇提浓缩液与所述水提浓缩液分别进行减压真空干燥至干膏状;
7)、将步骤6)中两种干膏混匀、粉碎、过筛,得相应干膏粉;
8)、分别取处方量的预胶化淀粉、微晶纤维素、交联聚乙烯吡咯烷酮、低取代羟丙基纤维素,过筛、与上述干膏粉按比例进行混匀;
9)、混匀后,以聚乙烯吡咯烷酮乙醇溶液为润湿剂,制软材;
10)、将上述软材过筛,制成颗粒,烘箱干燥,温度为60℃;
11)、将上述干燥后的颗粒过筛整粒;
12)、取处方量的滑石粉过筛并与上述颗粒混匀后,压片。
本发明在所述步骤3)中进行醇提时,丹参药材所需乙醇浓度为90%,提取2次,每次1小时,提取温度为90℃,溶媒量为4倍量;人参、红景天所需乙醇浓度为65%,提取2次,每次1小时,溶媒量为5倍量。
或所述步骤3)中进行醇提时,丹参药材所需乙醇浓度为95%,提取2次,每次1小时,提取温度为90℃,溶媒量为5倍量;人参、红景天所需乙醇浓度为70%,提取3次,每次2小时,溶媒量为6倍量。
或所述步骤3)中进行醇提时,丹参药材所需乙醇浓度为95%,提取3次,每次2小时,提取温度为90℃,溶媒量为6倍量;人参、红景天所需乙醇浓度为75%,提取3次,每次2小时,溶媒量为7倍量。
本发明在所述步骤4)中进行水提时,所需纯化水用量为6倍量,提取2次,每次1小时。
或所述步骤4)中进行水提时,所需纯化水用量为7倍量,提取2次,每次2小时。
或所述步骤4)中进行水提时,所需纯化水用量为8倍量,提取3次,每次2小时。
本发明在所述步骤4)和所述步骤5)的减压浓缩过程中,减压至相对密度为1.05~1.08。
本发明在所述步骤7)、所述步骤8)和所述步骤12)过筛目数应为80目。
本发明在所述步骤10)过筛目数应为40目。
本发明在所述步骤11)过筛目数应为16目。
本发明在所述步骤9)润湿剂应为5%聚乙烯吡咯烷酮的80%乙醇溶液。
本发明步骤8)干膏粉末与辅料粉末的比例为1.5:1;辅料比例应为:微晶纤维素:预胶化淀粉:交联聚乙烯吡咯烷酮:低取代羟丙基纤维素:滑石粉=48.5:13:16.25:20.25:2。
以下通过实验进一步阐述本发明所述保健食品的有益效果,这些实验包括CoCl2干预下的H9c2细胞的存活实验、小鼠常压耐缺氧实验、急性脑缺血性缺氧实验、亚硝酸钠中毒存活实验。
一、材料
1.实验试剂及仪器
METTLER-AE240电子分析天平(瑞士METTLER公司);HH-6数显恒温水浴锅(金坛市佳美仪器有限公司)KQ-250型超声波清洗器(昆山市仪器有限公司);ZTW调温电热套(北京市永光明医疗仪器厂);DZF-6050型真空干燥箱(上海博迅实业有限公司);HX-400A型高速中药粉碎机(浙江省永康市溪岸五金药具厂);RE-52A旋转蒸发器(上海亚荣生化仪厂);SHZ-Ⅲ型循环水真空泵(上海亚荣生化仪厂);UV-1700紫外分光光度计(日本岛津);RT-6100酶标分析仪(深圳雷杜);DMEM细胞培养基(美国Gibco公司);HEPES(美国Gibco公司);链霉素-青霉素溶液(美国Gibco公司);PBS粉剂(上海化学试剂公司);胰蛋白酶(美国Gibco公司);EDTA(美国Gibco公司);细胞活性检测试剂盒MTT(上海碧云天生物技术公司);大鼠心肌H9c2(ATCC细胞库);新生胎牛血清(美国Gibco公司);CoCl2(美国Sigma公司);钠石灰;亚硝酸钠;生理盐水;计时器。
红景天、丹参、人参药材购买于吉林省仙草医药药材有限公司,由我校中药鉴定教研室分别鉴定为《中国药典》2015年版一部项下收录品种,经检测三种药材均符合《中国药典》2015年版一部红景天、丹参、人参项下质量要求。
2.实验动物
SPF级雄性小鼠,体重18~22g,由长春宏达鼠厂提供,生产许可证号SCXK(吉)2008-0002。
二、方法
1.取指数生长期的H9c2细胞制成单细胞悬液,细胞密度为6×104个/ml,接种于96孔板,每孔100μl,置于37℃、5%CO2培养箱,用含10%FBS的培养液培养24小时,而后加入不同浓度的红景天、丹参、人参提取物培养液(培养液干预24小时),再加入含有浓度为50μmol/ml的CoCl2培养液干预6小时。MTT法测细胞存活率,以公式计算细胞存活率=OD实验组、对照组/OD正常组×100%。平行操作3次。
2.常压耐缺氧实验
分组:随机分为空白组、一种提高缺氧耐受力的保健食品低、中、高剂量组,每组12只。
给药方法:
空白组:生理盐水灌胃0.4ml;
一种提高缺氧耐受力的保健食品低、中、高剂量组:设3个剂量组,分别按0.0143g/ml、0.0429g/ml、0.1286g/ml进行灌胃0.4ml。
最后一次灌胃受试品1h后,将每只小鼠分别放入广口瓶内,瓶中预先装有钠石灰5g,瓶口提前均匀涂抹凡士林,将小鼠放入后立即盖严瓶口,计时,记录小鼠缺氧死亡的时间。
3.急性脑缺血性缺氧实验
分组:随机分为空白组、一种提高缺氧耐受力的保健食品低、中、高剂量组,每组12只。
给药方法:
空白组:生理盐水灌胃0.4ml;
一种提高缺氧耐受力的保健食品低、中、高剂量组:设3个剂量组,分别按0.0143g/ml、0.0429g/ml、0.1286g/ml进行灌胃0.4ml。
最后一次灌胃受试品1h后,进行自颈部断头处理,用秒表记录每只小鼠张口喘气的时间。
4.亚硝酸钠中毒存活实验
分组:随机分为空白组、一种提高缺氧耐受力的保健食品低、中、高剂量组,每组12只。
给药方法:
空白组:生理盐水灌胃0.4ml;
一种提高缺氧耐受力的保健食品低、中、高剂量组:设3个剂量组,分别按0.0143g/ml、0.0429g/ml、0.1286g/ml进行灌胃0.4ml。
最后一次灌胃受试品1h后,进行腹腔注射亚硝酸钠,立即计时,记录每只小鼠存活时间。
三、结果
红景天、丹参、人参提取物对H9c2细胞先预防再造模的细胞活性实验结果
实验结果得出,对H9c2细胞先加入药物进行预防,再进行CoCl2造模干预的细胞活性,通过这种实验方式,证明当红景天、丹参、人参提取物给药量为5~10μg/ml时,细胞状态良好。
小鼠常压耐缺氧、急性脑缺血性缺氧、亚硝酸钠中毒存活实验结果(n=10)
和空白组比较,本发明的一种提高缺氧耐受力的保健食品低、中、高剂量组,小鼠存活时间均显著延长,表明本发明的一种提高缺氧耐受力的保健食品具有明确的提高小鼠缺氧耐受力作用。
四、结论
缺氧是现代人群亚健康的最主要的原因之一,而且严重缺氧会导致心血管、肿瘤、癌症等疾病的发生,严重甚至死亡。由于现代仪器设备治疗的局限性,以及化学药物不同程度的副作用,因此如何利用毒性小,无副作用的中药及其复方制剂,加以中医基础理论,治疗亚健康状态及慢性疾病已然是一种趋势。
本发明以红景天、丹参、人参提取物进行药效筛选试验,结果表明,红景天、丹参、人参提取物具有不同程度的体内、体外的耐缺氧作用,均可延长小鼠存活时间,耐缺氧活性效果明显。所以本发明旨在对一种具有缺氧耐受力作用的保健食品,运用现代中药提取分离技术及现代制剂技术,将其研制成可缓解缺氧状态的中药片剂制剂。
以上是对本发明所提供的发明内容进行了详细介绍,对于本领域的一般技术人员来说,上述发明内容仅仅是对本发明的示意性实现方式的解释,本发明技术方案可以有改变之处。综上所述,本发明内容不应理解为对本发明的限制,在不背离本发明的权利要求情况下,并实现与本发明的相同的作用,均落在本发明保护范围之内。
Claims (10)
1.一种具有提高缺氧耐受力作用的保健食品,其特征在于,是由如下方法制备的:
1)、分别取处方量的红景天、丹参、人参,所述红景天、丹参、人参的重量比例为4:3:1;
2)、将丹参药材与红景天、人参药材分别加入两个提取罐中,并在提取罐中加入乙醇溶液;
3)、对所述提取罐中的材料进行乙醇提取,过滤,获得相应醇提液及药渣;
4)、在所述提取罐中加入纯化水与三味药渣混合,加热煎煮预定时间,对所得溶液过滤,获得水提液,并对所述水提液进行减压浓缩,获得水提浓缩液;
5)、将步骤3)中所获得的醇提液进行减压浓缩,回收乙醇至无醇味,获得醇提浓缩液;
6)、将所述醇提浓缩液与所述水提浓缩液分别进行减压真空干燥至干膏状;
7)、将步骤6)中两种干膏混匀、粉碎、过筛,得相应干膏粉;
8)、分别取处方量的预胶化淀粉、微晶纤维素、交联聚乙烯吡咯烷酮、低取代羟丙基纤维素,过筛、与上述干膏粉按比例进行混匀;
9)、混匀后,以聚乙烯吡咯烷酮乙醇溶液为润湿剂,制软材;
10)、将上述软材过筛,制成颗粒,烘箱干燥,温度为60℃;
11)、将上述干燥后的颗粒过筛整粒;
12)、取处方量的滑石粉过筛并与上述颗粒混匀后,压片。
2.根据权利要求1所述的一种具有提高缺氧耐受力作用的保健食品,其特征在于:在所述步骤3)中进行醇提时,丹参药材所需乙醇浓度为90~95%,提取2~3次,每次1~2小时,提取温度为90℃,溶媒量为4~6倍量;人参、红景天所需乙醇浓度为65~75%,提取2~3次,每次1~2小时,溶媒量为5~7倍量。
3.根据权利要求1所述的一种具有提高缺氧耐受力作用的保健食品,其特征在于:在所述步骤4)中进行水提时,所需纯化水用量为6~8倍量,提取2~3次,每次1~2小时。
4.根据权利要求1所述的一种具有提高缺氧耐受力作用的保健食品,其特征在于:在所述步骤4)和所述步骤5)的减压浓缩过程中,减压至相对密度为1.05~1.08。
5.根据权利要求1所述的一种具有提高缺氧耐受力作用的保健食品,其特征在于:在所述步骤7)、所述步骤8)和所述步骤12)过筛目数应为80目。
6.根据权利要求1所述的一种具有提高缺氧耐受力作用的保健食品,其特征在于:在所述步骤10)过筛目数应为40目。
7.根据权利要求1所述的一种具有提高缺氧耐受力作用的保健食品,其特征在于:在所述步骤11)过筛目数应为16目。
8.根据权利要求1所述的一种具有提高缺氧耐受力作用的保健食品,其特征在于:在所述步骤9)润湿剂应为5%聚乙烯吡咯烷酮的80%乙醇溶液。
9.根据权利要求1所述的一种具有提高缺氧耐受力作用的保健食品,其特征在于:步骤8)干膏粉末与辅料粉末的比例为1.5:1;辅料比例应为:微晶纤维素:预胶化淀粉:交联聚乙烯吡咯烷酮:低取代羟丙基纤维素:滑石粉=48.5:13:16.25:20.25:2。
10.如权利要求1~9任一所述的一种具有提高缺氧耐受力作用的保健食品的制备方法,其特征在于,包括下列步骤:
1)、分别取处方量的红景天、丹参、人参,所述红景天、丹参、人参的重量比例为4:3:1;
2)、将丹参药材与红景天、人参药材分别加入两个提取罐中,并在提取罐中加入乙醇溶液;
3)、对所述提取罐中的材料进行乙醇提取,过滤,获得相应醇提液及药渣;
4)、在所述提取罐中加入纯化水与三味药渣混合,加热煎煮预定时间,对所得溶液过滤,获得水提液,并对所述水提液进行减压浓缩,获得水提浓缩液;
5)、将步骤3)中所获得的醇提液进行减压浓缩,回收乙醇至无醇味,获得醇提浓缩液;
6)、将所述醇提浓缩液与所述水提浓缩液分别进行减压真空干燥至干膏状;
7)、将步骤6)中两种干膏混匀、粉碎、过筛,得相应干膏粉;
8)、分别取处方量的预胶化淀粉、微晶纤维素、交联聚乙烯吡咯烷酮、低取代羟丙基纤维素,过筛、与上述干膏粉按比例进行混匀;
9)、混匀后,以聚乙烯吡咯烷酮乙醇溶液为润湿剂,制软材;
10)、将上述软材过筛,制成颗粒,烘箱干燥,温度为60℃;
11)、将上述干燥后的颗粒过筛整粒;
12)、取处方量的滑石粉过筛并与上述颗粒混匀后,压片。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910037759.XA CN109588720A (zh) | 2019-01-15 | 2019-01-15 | 一种具有提高缺氧耐受力作用的保健食品及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910037759.XA CN109588720A (zh) | 2019-01-15 | 2019-01-15 | 一种具有提高缺氧耐受力作用的保健食品及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109588720A true CN109588720A (zh) | 2019-04-09 |
Family
ID=65965169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910037759.XA Pending CN109588720A (zh) | 2019-01-15 | 2019-01-15 | 一种具有提高缺氧耐受力作用的保健食品及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109588720A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110538242A (zh) * | 2019-09-26 | 2019-12-06 | 西藏中孚医药科技有限公司 | 一种复方红景天丹参含片的制备工艺 |
CN112690451A (zh) * | 2020-12-24 | 2021-04-23 | 孙立伟 | 人参醇提物在促睡眠的保健品或者食品中的应用 |
-
2019
- 2019-01-15 CN CN201910037759.XA patent/CN109588720A/zh active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110538242A (zh) * | 2019-09-26 | 2019-12-06 | 西藏中孚医药科技有限公司 | 一种复方红景天丹参含片的制备工艺 |
CN112690451A (zh) * | 2020-12-24 | 2021-04-23 | 孙立伟 | 人参醇提物在促睡眠的保健品或者食品中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101732683A (zh) | 一种治疗面部黄褐斑的中药制剂及其制备方法 | |
CN103271346B (zh) | 一种缓解体力疲劳保健食品 | |
CN104127699B (zh) | 益元养生制剂及其制备方法 | |
CN104587050B (zh) | 一种中药美体瘦身贴及其制备方法 | |
CN103372135B (zh) | 一种治疗心肾不交证导致的心脑血管疾病的中药组合物 | |
CN102225139A (zh) | 一种陈术健脾膏及其制备方法 | |
CN108524776A (zh) | 一种治疗气阴两虚型糖尿病的药物及其制备方法 | |
CN109588720A (zh) | 一种具有提高缺氧耐受力作用的保健食品及其制备方法 | |
CN104940645A (zh) | 一种具有美容养颜功能的铁皮石斛中药组合物及其制剂 | |
CN101199596A (zh) | 一种减轻癌症放、化疗毒副作用的中药组合物及其制备方法 | |
CN1306951C (zh) | 一种治疗气虚血瘀型胸痹的药物及其制备工艺 | |
CN104491342A (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN106579419A (zh) | 一种缓解疲劳、恢复体力、补充能量的功能食品组合物 | |
CN102441071B (zh) | 一种保健口服液 | |
CN101411830A (zh) | 一种治疗肝胆脾胃疾病的配方及其制剂方法 | |
CN102631538A (zh) | 一种治疗心脏病的中药 | |
CN109288904A (zh) | 预防或治疗心律失常的中药组合物及其制备方法和用途 | |
CN101507810B (zh) | 一种治疗心律失常的中成药制剂 | |
CN1709476A (zh) | 养心安眠胶囊 | |
CN102366458A (zh) | 一种治疗阴虚所致便秘的中药制剂及制备方法 | |
CN101884758B (zh) | 基于治未病和药食同源理论的防治脑血管病的食疗制剂 | |
CN101897940A (zh) | 一种抗疲劳的中药配方及其制备方法 | |
CN108836997A (zh) | 一种用于癌症康复治疗的药物及制备方法 | |
CN101703660B (zh) | 一种抗衰老药物 | |
CN1049143C (zh) | 一种治疗贫血病的中药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190409 |